Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ralph Lauren Corp (RL) vs Smith & Nephew plc (SNN) Price & Performance

Ralph Lauren CorpTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Ralph Lauren Corp vs Smith & Nephew plc — how do they compare? Ralph Lauren Corp trades at $368.77 (market cap $21.89B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Ralph Lauren Corp for 84 Days and Smith & Nephew plc for 120 Days on average.

RLSNN
Market Cap
$21.89B$11.10B
Volume
481,6171,051,703
Sector
Consumer CyclicalHealth
52-Week High
$414.25$37.17
52-Week Low
$309.29$26.42
Typical Hold Time
84 Days120 Days
Enterprise Value
$22.95B$14.13B
Dividend Yield
1.09%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ralph Lauren Corp

Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 exceeding the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent developments include global store expansion and sustainability initiatives under the Timeless by Design 2030 strategy.

RL presents a compelling investment case with strong profitability (37.54% ROE, 70.27% gross margins) and analyst consensus pointing to 26% upside to the $456.67 price target. However, the stock faces near-term technical headwinds and competitive pressures in the luxury apparel sector. The improving cash flow trajectory and dividend payments provide shareholder value support amid market volatility.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.

The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RL
100% Buy0% Sell
Avg holding period · 84 Days
SNN

No sentiment data available yet.

Top news

Latest headlines on both assets

About Ralph Lauren Corp

Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.

Read more on RL →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →